MyopiaCEDARNCT05650190
Spectacle Lens Visual Acuity Assessments Study
A study testing Novel spectacle lens design and Spectacle lenses in people with Myopia and Myopia Progression, run by SightGlass Vision, Inc. at 6 sites in United States.
Trial summary
This is a two-arm parallel group, non-dispensing study. Participants will be existing active CYPRESS Extension (CPRO-1802-002) subjects. Subjects will undergo additional visual performance assessments. Read more about this study
- Who is it for?
- Ages 9 to 14 yearsHealthy volunteers can take part
- Conditions the study is for
- Myopia, Myopia Progression, Juvenile Myopia
- What is being tested?
- Novel spectacle lens design and Spectacle lenses
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 51 participants
- Where
- 6 sitesUnited States
- Study dates
- 8 Dec 2022to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 9 to 14 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Existing subject from the CYPRESS Extension study (CPRO-1802-002)
- Ability to comply with study assessments
- The subject's parent(s) or legal guardian(s) must read, understand and sign the Statement of Informed Consent and receive a fully executed coy of the form
Who cannot join
- Any current ocular infection, inflammation or irritation likely to affect vision
Trial locations and contacts
6 sites in 1 country.
6 sites in 1 country
United States6 sites
Vision Optique
Houston, Texas, 77205
Sabal Eye Care
Longwood, Florida, 32779
SUNY School of Optometry
New York, New York, 10036
Kannarr Eye Care
Pittsburg, Kansas, 66762
Advanced Eyecare PC
Raytown, Missouri, 64133
William J Bogus, OD, FAAO
Salt Lake City, Utah, 84106
About this study
Official title: Spectacle Lenses Visual Acuity Assessments Study
This is a two-arm parallel group, non-dispensing study. Participants will be existing active CYPRESS Extension (CPRO-1802-002) subjects. Subjects will undergo additional visual performance assessments.
- Conditions
- Myopia, Myopia Progression, Juvenile Myopia
- Being tested
- Novel spectacle lens design, Spectacle lenses
- Medical subject headings
- Myopia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Novel spectacle lens designDevice
Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia
Spectacle lensesDevice
Single vision, impact resistant spectacle lenses
| Study group | Role | What they receive |
|---|---|---|
| Test Arm | Experimental | Single vision, impact resistant spectacle lenses; Test Arm Receives: Device: Novel spectacle lens design |
| Control Arm | Placebo comparator | Single vision, impact resistant spectacle lenses; Control Arm Receives: Device: Spectacle lenses |
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual Acuity
Reading Speed (maximum words per minute)
Measured: 15 minutes
Secondary outcomes (1)
Near Visual Acuity with Glare
Mean and Standard Deviation at 15 minutes (short duration test)
Measured: 15 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Dec 2022
- Study start8 Dec 2022
- Primary completion10 Feb 2023
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MyopiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 51 participants (actual)
Sponsor and investigators
- Lead sponsor
- SightGlass Vision, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05650190
- Sponsor's protocol ID
- CPRO-2209-001
- Acronym
- CEDAR
- Status last verified
- Apr 2026
- First submitted
- 28 Nov 2022
- Last updated
- 5 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 5 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Spectacle Lenses Visual Acuity Assessments Study
- ClinicalTrials.gov ID
- NCT05650190
- Acronym / sponsor ID
- CEDAR / CPRO-2209-001
- Conditions
- Myopia, Myopia Progression, Juvenile Myopia
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 51 participants (actual)
- Lead sponsor
- SightGlass Vision, Inc.Industry (pharma, biotech, devices)
- Study start
- 8 Dec 2022 (actual)
- Primary completion
- 10 Feb 2023 (actual)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 14 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a two-arm parallel group, non-dispensing study. Participants will be existing active CYPRESS Extension (CPRO-1802-002) subjects. Subjects will undergo additional visual performance assessments.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Test Arm | Experimental | Device: Novel spectacle lens designSingle vision, impact resistant spectacle lenses; Test Arm |
| Control Arm | Placebo comparator | Device: Spectacle lensesSingle vision, impact resistant spectacle lenses; Control Arm |
Who may qualify
- Ages
- 9 to 14 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- Existing subject from the CYPRESS Extension study (CPRO-1802-002)
- Ability to comply with study assessments
- The subject's parent(s) or legal guardian(s) must read, understand and sign the Statement of Informed Consent and receive a fully executed coy of the form
Key exclusion criteria (1 listed)
- Any current ocular infection, inflammation or irritation likely to affect vision
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Novel spectacle lens designUse of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia | Device | Test Arm |
| Spectacle lensesSingle vision, impact resistant spectacle lenses | Device | Control Arm |
Primary outcome
Visual Acuity
Time frame: 15 minutes
Reading Speed (maximum words per minute)
1 secondary outcome
Near Visual Acuity with Glare
Time frame: 15 minutes
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 May 2026.
Related trials for Myopia
RecruitingPhase 3
A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control
Myopia
Active, not recruitingPhase 4
Odyssey Evaluation in Post LASIK Patients
Cataract
Recruiting
Evaluation of Orthokeratology Lenses With a 5MM Optic Zone Diameter
Myopia, Astigmatism
Recruiting
Wavelength Intervention for Nearsighted Kids
Myopia
Not yet recruiting
SmoothCore Orthokeratology Plus M.O.V.E. Lenses vs. M.O.V.E. Lenses Alone for Myopia Control in Children With High Myopia
High Myopia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Novel spectacle lens design and Spectacle lenses in people with Myopia and Myopia Progression, run by SightGlass Vision, Inc. at 6 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 5 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual Acuity (time frame: 15 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2026.